Last reviewed · How we verify

tetracycline (BQ10) — Competitive Intelligence Brief

tetracycline (BQ10) (tetracycline (BQ10)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Tetracycline antibiotic. Area: Infectious Disease.

marketed Tetracycline antibiotic Bacterial 30S ribosomal subunit Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

tetracycline (BQ10) (tetracycline (BQ10)) — National Taiwan University Hospital. Tetracycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing peptide bond formation.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
tetracycline (BQ10) TARGET tetracycline (BQ10) National Taiwan University Hospital marketed Tetracycline antibiotic Bacterial 30S ribosomal subunit
Bethkis® Bethkis® Mylan Inc. marketed Aminoglycoside antibiotic Bacterial 30S ribosomal subunit
Tobramycin + Dexamethasone Tobramycin + Dexamethasone Umm Al-Qura University marketed Antibiotic + corticosteroid combination Bacterial 30S ribosomal subunit (tobramycin); glucocorticoid receptor (dexamethasone)
Minocycline vs Lymecycline Minocycline vs Lymecycline Darier marketed Tetracycline antibiotic Bacterial 30S ribosomal subunit
Tetracycline Pill Tetracycline Pill National Cheng-Kung University Hospital marketed Tetracycline antibiotic Bacterial 30S ribosomal subunit
Minocycline (yes/no) Minocycline (yes/no) Medical University of South Carolina marketed Tetracycline antibiotic Bacterial 30S ribosomal subunit
hand mixed tobramycin hand mixed tobramycin Washington University School of Medicine marketed Aminoglycoside antibiotic Bacterial 30S ribosomal subunit

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Tetracycline antibiotic class)

  1. OraPharma · 2 drugs in this class
  2. Vyne Therapeutics Inc. · 2 drugs in this class
  3. Beijing Tiantan Hospital · 1 drug in this class
  4. Clinica Universidad de Navarra, Universidad de Navarra · 1 drug in this class
  5. Darier · 1 drug in this class
  6. Edward Lain, MD · 1 drug in this class
  7. Generic (originally Pfizer) · 1 drug in this class
  8. Galderma R&D · 1 drug in this class
  9. Johns Hopkins University · 1 drug in this class
  10. Chinese University of Hong Kong · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). tetracycline (BQ10) — Competitive Intelligence Brief. https://druglandscape.com/ci/tetracycline-bq10. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: